Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evogene Ltd. (EVGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Evogene files reports with the U.S. Securities and Exchange Commission, including Form 20‑F and recurring Form 6‑K reports that furnish financial statements, operating and financial reviews, and information on corporate actions.
For investors analyzing Evogene’s AI‑driven life‑science business, Form 6‑K submissions are particularly important. These filings often include press releases and slide presentations for quarterly results, unaudited condensed consolidated financial statements for interim periods, and operating and financial review and prospects documents. Through these materials, readers can examine revenue contributions from subsidiaries, cost‑reduction measures, restructuring steps, and transactions such as the sale of most of Lavie Bio’s activity and the transfer of the MicroBoost AI for Ag platform to ICL.
Evogene’s filings can also reference shareholder meeting outcomes, proxy materials, and incorporation by reference into registration statements on Form F‑3 and Form S‑8. Together, these documents outline the company’s capital markets activity, equity compensation plans and other corporate matters.
On Stock Titan, EVGN filings are updated as they are furnished to EDGAR, and AI‑powered tools summarize key points from lengthy documents. Users can quickly identify items such as interim financial trends, changes in subsidiary structure, or strategic shifts around tech‑engines like ChemPass AI, MicroBoost AI and GeneRator AI, without reading every page of the original filing.
Evogene Ltd. filed a Form 3 detailing the equity holdings of its Chief Financial Officer, Eldad Yaron. He holds 4,100 ordinary shares underlying restricted share units that began vesting on April 1, 2023 at 6.25% per quarter over four years.
He also holds stock options over 15,000 ordinary shares at an exercise price of 12.584 per share, vesting from March 30, 2022 with 25% after one year and 6.25% per quarter thereafter until fully vested on the four-year anniversary. Additional options cover 60,000 ordinary shares at an exercise price of 2.300 per share, vesting 6.25% per quarter over four years from November 20, 2024.
Evogene Ltd. director and President & CEO Haviv Ofer filed an initial ownership report showing he holds stock options over ordinary shares in the company. These include options over 22,500 shares at an exercise price of 51.9600 per share expiring on August 8, 2027, 50,000 shares at 10.5000 per share expiring on April 21, 2030, and 52,800 shares at 1.6600 per share expiring on December 23, 2034. A footnote explains that the options granted on December 23, 2024 vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal quarterly installments of 6.25% over the next twelve quarters.
Evogene Ltd. director Falk Dan Michael reported his initial holdings of stock options linked to the company’s ordinary shares. The Form 3 shows four option grants with exercise prices of $10.51, $6.03, $7.16, and $1.29 per share and expiration dates ranging from September 2032 to August 2035. These options cover 1,800, 1,800, 1,800 and 2,500 underlying ordinary shares, all held directly. A footnote explains that the 2,500-share grant vests in four equal quarterly installments of 25% each, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.
Evogene Ltd. reported 2025 results showing a smaller overall loss alongside a major strategic shift toward its ChemPass AI generative small‑molecule platform. Net loss for 2025 narrowed to approximately $7.8 million from about $18.1 million, mainly due to lower operating expenses and a $6.4 million gain on the sale of Lavie Bio and MicroBoost AI for Ag to ICL, recorded in $5.7 million of income from discontinued operations.
Full‑year revenues fell to roughly $3.9 million from $5.6 million as certain AgPlenus and Corteva revenues and Casterra seed sales declined. A $2.2 million Casterra inventory impairment pushed 2025 cost of revenues to about $4.1 million, driving an operating loss of $14.0 million. Cash, cash equivalents and short‑term deposits were about $13.0 million at year‑end, after using $13.5 million in operating cash during 2025, while management exited non‑core assets, resized the organization and highlighted new AI collaborations with Google Cloud in pharma and agriculture.
Evogene Ltd. is outlining a strategic transformation centered on its ChemPass AI™ computational chemistry engine. After reassessing its technology and capital allocation in 2025, the company chose to focus resources on designing small molecules for two core markets: human health therapeutics and agricultural chemicals.
Evogene consolidated activity around ChemPass AI™, discontinued non-core work, divested misaligned subsidiaries, resized its organization and built a business development team aligned with this focused strategy. The platform operates on a 38‑billion‑molecule universe, aiming to generate novel, highly active, synthesizable compounds that meet complex multi‑parameter development requirements from the outset.
The company highlights collaborations in human health with biotechnology and academic partners, and in agriculture through its AgPlenus subsidiary, including relationships with Bayer and Corteva. It reports completion of key divestments, such as Lavie Bio’s sale to ICL and licensing of Biomica’s lead oncology candidate to Lishan Pharmaceuticals, while retaining exposure to assets like Casterra.
Evogene Ltd. entered a warrant inducement agreement with an existing institutional investor, leading to the cash exercise of 3,384,616 existing warrants at a reduced exercise price of $1.00 per share for approximately $3.4 million in gross proceeds. In return, Evogene will issue 5,076,924 new Series A-1 and Series B-1 warrants with a $1.25 exercise price, five-year and 18‑month terms, and a 4.99% ownership cap. The company plans to use the net proceeds for working capital and general corporate purposes and will seek to register the resale of shares underlying the new warrants on a Form F‑3. Evogene agreed to short-term restrictions on issuing additional equity or entering variable rate transactions, with limited exceptions including a potential at‑the‑market program via its advisor, A.G.P./Alliance Global Partners.
Evogene Ltd. reports that its subsidiary Biomica has granted Shanghai Lishan Biopharmaceuticals an exclusive worldwide license for BMC128, a microbiome-based therapy designed to enhance anti-tumor immune activity in renal cell carcinoma and non-small cell lung cancer.
Lishan Biotech will lead global clinical development, manufacturing and commercialization of BMC128, which is completing a Phase 1 study and has shown an excellent safety profile with early signs of efficacy, including many patients with previously progressive disease achieving stable disease. Biomica is eligible for development and sales milestone payments and royalties on future commercial sales under the agreement.
Evogene Ltd. reports a planned change in its senior finance leadership. Chief Financial Officer Yaron Eldad will resign effective March 31, 2026, for personal reasons, and the company states there was no disagreement regarding its operations, policies, or practices. VP Finance Polina Ravzin, who has served in that role since 2022 and previously held finance positions at DSIT Solutions Ltd. and Acorn Energy Inc., will continue as VP Finance while also taking on CFO responsibilities.
Evogene Ltd. submitted a Form 6-K announcing that it has released its financial results for the third quarter ended September 30, 2025. The company also scheduled a conference call on November 20, 2025 to discuss these quarterly results and made an investor slide presentation available.
The third quarter 2025 financial results are provided in a press release attached as Exhibit 99.1, and the accompanying slide deck is attached as Exhibit 99.2. The GAAP financial statement tables in the press release are incorporated by reference into Evogene’s existing registration statements on Form F-3 and multiple Form S-8 filings, so they now form part of those registration materials from the date of this Form 6-K.